Friedreich ataxia (FRDA) is an autosomal recessive degenerative disease caused either by an intronic GAA triplet repeat expansion that suppresses the expression of the frataxin gene on chromosome 9q13, or, rarely, by point mutations in the frataxin gene. We investigated the expression of the mouse frataxin homologue during embryonic development by Northern blot analysis and RNA in situ hybridization. Very faint expression could be detected from E10.5 in the neuroepithelium and more clearly from E12.5 in the developing central nervous system. At E14.5, frataxin was expressed at a much higher level that remained constant into the postnatal period. Maximum expression was observed in the spinal cord, particularly at the thoracolumbar level, and in the dorsal root ganglia. Significant levels of transcript could also be detected in the proliferating cells in the periventricular zone, in the cortical plates, in the heart, in the axial skeleton, and in some epithelial and mesenchymal tissues. Overall, the distribution of frataxin mRNA was in good accordance with previous data from Northern analysis of adult human tissues, the major discrepancy being the expression in mouse embryonic cerebral cortex which was not observed in adult human brain. The tissues expressing frataxin during development appear to be those that become dysfunctional or atrophied in FRDA. Overall, our data suggest that frataxin is a protein whose expression is cell-specific and developmentally regulated. 1997 Academic Press
INTRODUCTION
Friedreich ataxia (FRDA) is an autosomal recessive degenerative disease characterized by progressive gait and limb ataxia, signs of axonal sensory neuropathy, pyramidal weakness of the legs, and dysarthria (Geoffroy et al., 1976; Harding, 1981) . A hypertrophic cardiomyopathy is found in almost all affected individuals (Harding and Hewer, 1983) , while up to 85% of patients have kyphoscoliosis, and about half have pes cavus. Less frequently observed are optic atrophy and sensorineural hearing loss, which occur in 20-30% of the cases, diabetes mellitus, which is seen in about 10% of the cases, and carbohydrate intolerance, which is present in an additional 20% (Finocchiaro et al., 1988) . The age of onset is usually around puberty and almost always before 25 (Harding, 1981) , but can occasionally be later. Most patients are wheelchair bound by their late twenties and currently there is no treatment to slow the progression of the disease.
The first pathologic changes are thought to occur in the dorsal root ganglia with loss of large sensory neurons, followed by deterioration of the sensory posterior columns, spinocerebellar tracts, and corticospinal motor tracts of the spinal cord, as well as atrophy of large sensory fibers in peripheral nerves (Lamarche et al., 1984) . In the medulla and pons atrophy mostly involves the somatosensory system and occasionally the auditory and the vestibular systems. The cerebellar cortex is affected only late in the course of the disease, with some Purkinje cell loss, but the dentate nuclei are severely atrophied. Degenera-
